Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04135118
Other study ID # OUS P360
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2, 2020
Est. completion date September 1, 2022

Study information

Verified date December 2023
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Adenomyosis is a disease where ectopic endometrial glands affect the muscular wall of the uterus. Women that suffer from dysmenorrhea or infertility caused by adenomyosis need to confirm or rule out adenomyosis, and therefore tools for non-histologic confirmation of adenomyosis are indubitably required. Transvaginal ultrasound has been shown to be useful in diagnosing adenomyosis, but the interpretation of findings requires significant expertise in ultrasound and experience with diagnosing adenomyosis. This is because adenomyosis shows a very heterogeneous appearance in ultrasound. There are many different diagnostic signs that have to be considered and weighed. In a previous study, the investigators have developed a diagnostic algorithm that helps clinicians diagnose adenomyosis with transvaginal ultrasound and a clinical examination. It showed good diagnostic accuracy and seemed to be very robust with regards to artifacts and experience of the examiner. It is now necessary to validate this prediction model in a new, prospective study so it can be used in clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date September 1, 2022
Est. primary completion date June 23, 2022
Accepts healthy volunteers No
Gender Female
Age group N/A to 52 Years
Eligibility Inclusion Criteria: - Premenopausal (defined by having had menstruation the last six month) - If amenorrhea with levonorgestrel intrauterine device, the woman should be < 45 years old - Hysterectomy planned due to a benign condition - Hysterectomy does not require morcellation it is allowed to divide the uterus into 2-3 pieces, given that the orientation of the specimen is still possible for the pathologist) - Written consent is given - Can communicate in Norwegian or English at the Norwegian study sites, and Finnish, Swedish or English at the Finnish study site. Exclusion Criteria: - Gynecological cancer present at the time of inclusion - Use of gonadotropin-releasing hormone agonist or antagonist within the last 3 months prior to the ultrasound evaluation - Prior endometrial ablation or resection - Postmenopausal status or no menstrual bleeding for the last 6 months, or amenorrhea with levonorgestrel-intrauterine device and age >45 years. - Need for morcellation of the uterus

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Finland Turku University Hospital Turku
Norway Akershus University Hospital, Dept. of gynecology Lørenskog Akershus
Norway Department of Gynecology, Oslo University Hospital Ullevål and Rikshospital Oslo
Norway Sykehuset i Vestfold Tønsberg Vestfold
Norway St. Olavs Hospital, Dept. of Gynecology Trondheim Trøndelag

Sponsors (5)

Lead Sponsor Collaborator
Oslo University Hospital St. Olavs Hospital, The Hospital of Vestfold, Turku University Hospital, University Hospital, Akershus

Countries where clinical trial is conducted

Finland,  Norway, 

References & Publications (1)

Tellum T, Nygaard S, Skovholt EK, Qvigstad E, Lieng M. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018 Oct;110(5):957-964.e3. doi: 10.1016/j.fertnstert.2018.06.009. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of the prediction model for adenomyosis Diagnostic accuracy will be described using sensitivity (in %), specificity (in %), positive predictive value (in %), negative predictive value (in %), positive likelihood ratio (calculated by sensitivity/1-specificity), negative likelihood ratio (calculated as 1-sensitivity/specificity) and the area under the receiver-operator curve (as calculated with the (0-1) of the model. 1 year
Secondary Intraclass correlation coefficient (ICC) between readers ICC values are categorized as follows: 0-0.20, slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1, almost perfect agreement 2 years
See also
  Status Clinical Trial Phase
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Recruiting NCT04209127 - Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis N/A
Completed NCT05751876 - Dienogest in Perimenopausal Women With Adenomyosis
Recruiting NCT01048931 - Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Phase 3
Active, not recruiting NCT06223464 - Evaluation of the Relationship Between Adenomyosis and Elastographic Properties of the Cervix
Completed NCT05419414 - The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis N/A
Recruiting NCT05152667 - Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin
Not yet recruiting NCT03654144 - Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Phase 4
Completed NCT01992718 - What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Early Phase 1
Completed NCT02192606 - Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? N/A
Recruiting NCT02495311 - The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
Recruiting NCT03742843 - A Multi-omics Study of Adenomyosis
Recruiting NCT04481321 - Clinical and Molecular Study of Endometriosis and Adenomyosis
Recruiting NCT04894292 - The Effect of Adenomoyosis on Pregnancy Outcomes
Completed NCT03520439 - Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Phase 2/Phase 3
Recruiting NCT05937490 - Adenomyosis and ART Phase 4
Recruiting NCT06373822 - New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs
Completed NCT01821001 - Vaginal Bromocriptine for Treatment of Adenomyosis Phase 1
Recruiting NCT04295109 - Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function N/A
Recruiting NCT04356664 - Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Phase 2/Phase 3